ANI Pharmaceuticals said Thursday it initiated a phase 4 trial at Massachusetts General Hospital to evaluate the safety and efficacy of two dosing levels of purified Cortrophin gel in treating acute gout flares.
The company said Cortrophin gel is approved for short-term use as an adjunct therapy during acute episodes of gouty arthritis but is not for intravenous administration.
The study aims to further assess its clinical benefits and inform optimal dosing strategies, it added.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。